<DOC>
	<DOC>NCT00456053</DOC>
	<brief_summary>The purpose of this study is to test the safety and efficacy of FG-2216 in the treatment of patients with renal anemia who are not receiving erythropoietin and who are not on dialysis.</brief_summary>
	<brief_title>A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human Erythropoietin</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Stage 3 or 4 chronic kidney disease appropriate hemoglobin levels Neovascular age related macular degeneration requiring treatment Macular edema or proliferative retinopathy in diabetic subjects, requiring treatment Any history of malignancy Therapy with recombinant erythropoietin or red blood cell transfusion within 4 weeks Renal Transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Renal Anemia</keyword>
	<keyword>Renal Failure</keyword>
	<keyword>Kidney Disease</keyword>
	<keyword>Human EPO</keyword>
</DOC>